LIANBIO |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2808 USD | -5.77% |
|
-3.17% | -93.72% |
| 03-18 | LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index | CI |
| 03-15 | ADRs End Lower; Akso Health Group Declines 23% | DJ |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 178M 243M |
|---|---|---|---|---|---|
| Net income 2021 | -196M -268M | Net income 2022 | -110M -150M | EV / Sales 2021 | - |
| Net cash position 2021 | 378M 517M | Net cash position 2022 | 298M 407M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-1.08
x | P/E ratio 2022 |
-1.6
x | Employees | 163 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 40.81% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -5.77% | ||
| 1 week | -3.17% | ||
| Current month | -13.07% | ||
| 1 month | -13.60% | ||
| 3 months | -93.31% | ||
| 6 months | -92.55% | ||
| Current year | -93.72% |
1 week
0.28
0.31
1 month
0.280.35
Current year
0.244.99
1 year
0.244.99
3 years
0.2416.37
5 years
0.2416.37
10 years
0.2416.37
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Stone
CEO | Chief Executive Officer | 44 | 19-09-30 |
Levvy Lv
PRN | Corporate Officer/Principal | 42 | 20-03-31 |
Nathan Chen
LAW | General Counsel | 56 | 20-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 51 | 20-07-31 | |
Adam Stone
CEO | Chief Executive Officer | 44 | 19-09-30 |
Wei Wei Chen
BRD | Director/Board Member | 58 | 22-04-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.12% | 4 M€ | -27.92% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.2808 | -5.77% | 10,871 |
| 24-04-25 | 0.298 | +6.43% | 5,242 |
| 24-04-24 | 0.28 | -1.06% | 20,213 |
| 24-04-23 | 0.283 | +0.18% | 186,926 |
| 24-04-22 | 0.2825 | -2.59% | 6,172 |
Delayed Quote OTC Markets, April 26, 2024 at 03:59 pm
More quotes
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -93.72% | 30.37M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- LIANY Stock
